

 참고 문헌

1. Al-Badr A, Ross S, Soroka D, Drutz HP. What is the available evidence for hormone replacement therapy for women with stress urinary incontinence. *J Obstet Gynecol Can* 2003;25:567-74.
2. Barlow DH, Cardozo LD, Francis RM, Griffin M, Hart DM, Stephens E, et al. Urogenital ageing and its effect on sexual health in older British women. *Br J Obstet Gynecol* 1997;104:87-91.
3. Batra S, Andersson KE. Oestrogen-induced changes in muscarinic receptor density and contractile responses in the female rabbit urinary bladder. *Acta Physiol Scand* 1989;137:135-41.
4. Benness C, Gangar K, Cardozo LD, Cutner A, Whitehead M. Do progestogens exacerbate urinary incontinence in women on HRT? *NeuroUrol Urodyn* 1991;10:316-8.
5. Blakeman PJ, Hilton P, Bulmer JN. Cellular proliferation in the female lower urinary tract with reference to estrogen status. *Br J Obstet Gynaecol* 2001;108:813-6.
6. Blakeman PJ, Hilton P, Bulmer JN. Oestrogen and progesterin receptor expression in the female lower urinary tract, with reference to oestrogen status. *BJU Int* 2000;86:32-8.
7. Brandberg A, Mellström D, Samsioe G. Low dose oral estriol treatment in elderly women with urogenital infections. *Acta Obstet Gynecol Scand Suppl* 1987;140:33-8.
8. Brocklehurst JC. Ageing of the human bladder. *Geriatrics* 1972;27:154.
9. Callaghan SM, Creed KE. The effect of estrogens on spontaneous activities and responses to phenylephrine of the mammalian urethra. *J Physiol* 1985;358:35-46.
10. Capobianco G, Donolo E, Borghero G, Dessole F, Cherchi PL, Dessole S. Effects of intravaginal estriol and pelvic floor rehabilitation on urogenital aging in postmenopausal women. *Arch Gynecol Obstet* 2012;285(2):379-403.
11. Cardozo L, Lose G, McClish D, Versi E. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. *Acta Obstet Gynecol Scand* 2004;83:892-7.
12. Cardozo LD, Benness C, Abbot D. Low dose oestrogen prophylaxis for recurrent urinary tract infections in elderly women. *Br J Obstet Gynecol* 1998;105:403-7.
13. Cardozo LD, Lose G, McClish D, Versi E, de Koning Gans H. A systematic review of estrogens for recurrent urinary tract infections: third report of the hormones and urogenital therapy (HUT) committee. *Int Urogynecol J Pelvic Floor Dysfunct* 2001;12:15-20.
14. Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CM. Oestrogen therapy for urinary incontinence in postmenopausal women. *Cochrane Database Syst Rev* 2009; CD001405.
15. Collas DM, Malone Lee J. Age associated changes in detrusor sensory function in women with lower urinary tract symptoms. *Int Urogynecol J* 1996;7:24-9.
16. Cutner A, Burton G, Cardozo LD, Wise BG, Abbott D, Studd J. Does progesterone cause an irritable bladder? *Int Urogynecol J* 1993;4:259-61.
17. Di Donato V, Schiavi MC, Iacobelli V, D'oria O, Kontopantelis E, Simoncini T, et al. Ospemifene for the treatment of vulvar and vaginal atrophy: A meta-analysis of randomized trials. Part I: Evaluation of efficacy. *Maturitas* 2019;121:86-92.
18. Elliott RA, Castleden CM, Miodrag A, Kirwan P. The direct effects of diethylstilboestrol and nifedipine on the contractile responses of isolated human and rat detrusor muscles. *Eur J Clin Pharmacol* 1992;43:149-55.
19. Elliott RA, Castleden CM. Effects of progestogens and oestrogens on the contractile response of rat detrusor muscle to electrical field stimulation. *Clin Sci* 1994;87:337-42.
20. Endo RM, Girao MJ, Sartori MG, Simões MJ, Baracat EC,

- Rodrigues de Lima G. Effect of estrogen-progestogen hormonal replacement therapy on peri-urethral and bladder vessels, *Int Urogynecol J Pelvic Floor Dysfunct* 2000;11:120-3.
21. Eriksen B. A randomized open parallel group study on the preventative effect of an estradiol releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. *Am J Obstet Gynecol* 1999;180:1072-9.
 22. Fantl JA, Cardozo LD, McClish DK. Estrogen therapy in the management of urinary incontinence in postmenopausal women: a meta-analysis. First report of the Hormones and Urogenital Therapy Committee (HUT). *Obstet Gynecol* 1994;83:12-8.
 23. Grodstein F, Lifford K, Resnick NM, Curhan GC. Postmenopausal hormone therapy and risk of developing urinary incontinence. *Obstet Gynecol* 2004;103:254-60.
 24. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. *JAMA* 2005;293:935-48.
 25. Hextall A, Bidmead J, Cardozo LD, Hooper R. The impact of the menstrual cycle on urinary symptoms and the results of urodynamic investigation. *Br J Obstet Gynaecol* 2001;108:1193-6.
 26. Iosif CS, Bekassey Z. Prevalence of genito-urinary symptoms in the late menopause. *Acta Obstet Gynecol Scand* 1984;63:257-60.
 27. Jackson S, James M, Abrams P. The effect of oestradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. *BJOG* 2002;109:339-44.
 28. Kolbl H, Strassegger H, Riis PA. Morphological and functional aspects of pelvic floor muscles in patients with pelvic relaxation and genuine stress incontinence. *Obstet Gynecol* 1989;74:789-95.
 29. Malone Lee J, Waheda I. The characterisation of detrusor contractile function in relation to old age. *Br J Urol* 1993;72:873-80.
 30. Mishra GD, Cardozo L, Kuh D. Menopausal transition and the risk of urinary incontinence: results from a British prospective cohort. *BJU Int* 2010;106:1170-5.
 31. Moehrer B, Hextall A, Jackson S. Oestrogens for urinary incontinence in women. *Cochrane Database Syst Rev* 2003; CD001405.
 32. National Institute for Health and Clinical Excellence. Urinary incontinence 2006. <http://www.nice.org.uk/nice/media/pdf/CG40fullguideline.pdf>. Accessed 19/09/2009.
 33. Parsons CL, Schmidt JD. Control of recurrent lower urinary tract infection in the postmenopausal woman. *J Urol* 1982;128:1224-6.
 34. Perrucchini D, DeLancey JOL, Patane L, Kataria T, Peschers U, Ashton Miller JA. The number and diameter of striated muscle fibres in the female urethra. *Neurourol Urodyn* 1997;16:405-6.
 35. Perrotta C, Aznar M, Mejia R, Albert X, Ng CW. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. *Cochrane Database Syst Rev* 2008;16(2):CD005131.
 36. Privette M, Cade R, Peterson J, Mars D. Prevention of recurrent urinary tract infections in postmenopausal women. *Nephron* 1988;50:24-7.
 37. Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. *N Engl J Med* 1993;329:753-6.
 38. Rud T. The effects of estrogens and gestagens on the urethral pressure profile in urinary continent and stress incontinent women. *Acta Obstet Gynecol Scand* 1980;59:265-70.
 39. Russo E, Caretto M, Giannini A, Bitzer J, Cano A, Ceausu I, et al. Management of urinary incontinence in postmenopausal women: An EMAS clinical guide. *Maturitas* 2021;143:223-30.
 40. Serati M, Salvatore S, Ucella S, Cardozo L, Bolis P. Is there a synergistic effect of topical estrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity- *Eur Urol* 2009;55:713-9.
 41. Shamliyan TA, Kane RL, Wyman J, Wilt TJ. Systematic review: randomised controlled trials of nonsurgical treatments for urinary incontinence in women. *Ann Intern Med* 2008;148:459-73.
 42. Shapiro E. Effect of estrogens on the weight and muscarinic cholinergic receptor density of the rabbit bladder and urethra. *J Urol* 1986 135:1084-7.
 43. Steinauer JE, Waetjen LE, Vittinghoff E, Subak LL, Hulley SB, Grady D, et al. Postmenopausal hormone therapy: does it cause incontinence. *Obstet Gynecol* 2005;106:940-5.
 44. The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. *Menopause : The journal of The North American Menopause Society* 2020;27(9):976-92.
 45. Waetjen LE, Feng WY, Ye J, Johnson WO, Greendale GA, Sampsel CM, et al. Factors associated with worsening and improving urinary incontinence across the menopausal transition. *Obstet Gynecol* 2008;111:667-77.
 46. Wilson PD, Faragher B, Butler B, Bu'Lock D, Robinson EL, Brown AD. Treatment with oral piperazine oestrone sulphate for genuine stress incontinence in postmenopausal women. *Br J Obstet Gynaecol* 1987;94:568-74.